



**Date: 9 March 2018**

**Sydney, Australia**

**ASX: NOX**

**Noxopharm  
Limited**

ABN 50 608 966 123

**Registered Office:**  
and  
**Operations Office:**  
Suite 3, Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

**Board of Directors**

**Mr Peter Marks**  
Chairman  
Non-Executive  
Director

**Dr Graham Kelly**  
Chief Executive  
Officer  
Managing Director

**Dr Ian Dixon**  
Non-Executive  
Director

**FNN Interview with Noxopharm CEO explains interim clinical data released this week**

Noxopharm Limited (ASX:NOX) is pleased to provide shareholders with a video interview with Finance News Network discussing this week's interim clinical data from the first chemotherapy trial, CEP-1.

The data was presented at the 2018 European Society for Medical Oncology (ESMO) International Congress on Targeted Anticancer Therapies in Paris.

To view the full interview and transcript please visit this link;

<https://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1162>

For more information please go to the Noxopharm website;

[www.noxopharm.com](http://www.noxopharm.com)

-----

**About NOX66**

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour.

Idronoxil is a kinase inhibitor that works by inhibiting a range of enzymes including sphingosine kinase and PI3 kinase that regulate cell pro-survival mechanisms and which are over-expressed in cancer cells, as well as inhibiting external NADH oxidase Type 2 (ENOX 2) which is responsible for maintaining the transmembrane electron potential (TMEP) in the plasma membrane of cancer cells and whose expression is limited to cancer cells. Inhibition of these enzymes results in disruption of key downstream pro-survival mechanisms including

resistance mechanisms, sensitizing the cancer cell to the cytotoxic effects of chemotherapy drugs and radiotherapy. Idronoxil also activates the immune system, increasing the activity of human natural killer cells.

NOX66 is a first-in-class anti-drug with dual cytotoxic and immunological functions.

### **About Noxopharm**

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of drug- and radio-resistance in cancer cells, the major hurdles facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs that are held by subsidiary company, Nyrada, Inc.

### **Investor & Corporate Enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

### **Company Secretary:**

David Franks

T: +61 2 9299 9690

E: [dfranks@fa.com.au](mailto:dfranks@fa.com.au)

[www.noxopharm.com](http://www.noxopharm.com)

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.